Ascendis Historical Cash Flow
| ASND Stock | USD 136.00 0.32 0.23% |
Analysis of Ascendis Pharma cash flow over time is an excellent tool to project Ascendis Pharma AS future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 270.1 M or Other Cashflows From Financing Activities of 8.9 M as it is a great indicator of Ascendis Pharma ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Ascendis Pharma AS latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ascendis Pharma AS is a good buy for the upcoming year.
Ascendis |
About Ascendis Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Ascendis balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Ascendis's non-liquid assets can be easily converted into cash.
Ascendis Pharma Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Ascendis Pharma AS to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Ascendis Pharma operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Ascendis Pharma's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Ascendis Pharma AS current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At present, Ascendis Pharma's Other Cashflows From Financing Activities is projected to increase significantly based on the last few years of reporting. The current year's Depreciation is expected to grow to about 19.9 M, whereas Change In Cash is projected to grow to (50 M).
Ascendis Pharma cash flow statement Correlations
Click cells to compare fundamentals
Ascendis Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ascendis Pharma cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (75.4M) | (5.6M) | (5.5M) | (55.3M) | (78.3M) | (74.3M) | |
| Change In Cash | 320.2M | (13.6M) | (138.3M) | (1.5M) | (52.6M) | (50.0M) | |
| Stock Based Compensation | 37.5M | 53.2M | 66.8M | 64.2M | 66.7M | 70.0M | |
| Free Cash Flow | (181.1M) | (293.1M) | (441.9M) | (510.2M) | (469.8M) | (446.3M) | |
| Change In Working Capital | 4.1M | (964K) | (48.9M) | (18.6M) | (99.8M) | (94.8M) | |
| Begin Period Cash Flow | 277.9M | 598.1M | 584.5M | 446.3M | 444.8M | 270.1M | |
| Other Cashflows From Financing Activities | (31.7M) | 26.9M | 44.7M | 5.2M | 8.5M | 8.9M | |
| Depreciation | 6.7M | 9.4M | 15.4M | 18.0M | 18.9M | 19.9M | |
| Other Non Cash Items | (5.9M) | 86.0M | (67.0M) | 18.6M | 21.0M | 22.0M | |
| Capital Expenditures | 5.2M | 21.6M | 24.2M | 14.5M | 2.4M | 2.3M | |
| Total Cash From Operating Activities | (175.9M) | (271.5M) | (417.6M) | (495.7M) | (467.4M) | (444.0M) | |
| Change To Account Receivables | (1.9M) | (1.9M) | (6.7M) | (11.3M) | (32.1M) | (30.5M) | |
| Net Income | (218.0M) | (419.0M) | (383.6M) | (583.2M) | (481.4M) | (457.4M) | |
| Total Cash From Financing Activities | 493.6M | 602.7M | 351.4M | 396.8M | 134.3M | 236.3M | |
| End Period Cash Flow | 598.1M | 584.5M | 446.3M | 444.8M | 392.2M | 304.6M | |
| Sale Purchase Of Stock | 529.3M | 0.0 | (21.6M) | (105.3M) | (1.8M) | (1.7M) | |
| Total Cashflows From Investing Activities | (5.2M) | (291.2M) | (110.6M) | 61.7M | 55.6M | 58.3M | |
| Change To Operating Activities | 4.8M | (6.4M) | (11.2M) | (6.4M) | (5.8M) | (5.5M) | |
| Change To Netincome | 31.3M | 138.9M | (549K) | 88.2M | 101.4M | 106.4M | |
| Change To Liabilities | 1.5M | 7.4M | 44.4M | 54.6M | 62.8M | 65.9M | |
| Investments | (5.2M) | (291.2M) | (86.3M) | 61.7M | 279.0M | 293.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.82) | Revenue Per Share 5.595 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (8.18) |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.